OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
$4.98
arrow_upward
+1.12%(+0.055) 1D
Okt 16, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa OPHLY...
Buksan
$5.05
Mataas
$5.07
Mababa
$4.98
Mkt. cap
1.20T
Avg. na dami
62.80K
Dami
20.91K
Mataas nang 52-wk
$5.75
Mababa nang 52-wk
$3.82
Beta
0.21
Mga natitirang share
1.50B
Bilang ng mga empleyado
4K
Buksan
$5.05
Mataas
$5.07
Mababa
$4.98
Mkt. cap
1.20T
Avg. na dami
62.80K
Dami
20.91K
Mataas nang 52-wk
$5.75
Mababa nang 52-wk
$3.82
Beta
0.21
Mga natitirang share
1.50B
Bilang ng mga empleyado
4K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Investor's Business Daily
·
1 araw ang nakalipas
9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation
Bloomberg.com
·
1 araw ang nakalipas
S&P 500 Steady as Warsh Boosts Expectations of Rate Hold
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Tungkol sa Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Mga Empleyado4.21K
Itinatag1717
HeadquartersLungsod ng Osaka, Prepektura ng Osaka, Japan
Sektor-
Websiteono-pharma.com